Table 4.
Details of the seven participants who discontinued olanzapine due to an adverse effect
| Participant | Abnormal lab | Olanzapine details | Weight restored as per physician | % of TGW | |
|---|---|---|---|---|---|
| Days of treatment* | Max dose (mg/day) | ||||
| 1 | ↑ ALT ↑ AST |
60 | 5 | No | 91.58 |
| 2 | ↑ ALT ↑ AST |
33 | 2.5 | No | 95.41 |
| 3a | ↑ ALT ↑ AST |
26 | 2.5 | No | 82.67 |
| 4b | ↑ cholesterol ↑ triglycerides |
28 | 5 | Yes | 94.34 |
| 5 | ↑ cholesterol ↑ HDL ↑ LDL ↑ prolactin |
34 | 5 | No | 81.40 |
| 6 | ↑ cholesterol ↑ HDL ↑ prolactin |
16 | 2.5 | No | 84.81 |
| 7c | ↑ amylase | 37 | 2.5 | No | 95.79 |
*
Number of days the participant was taking olanzapine when a side effect resulted in the discontinuation of olanzapine treatment
a
Participant also had a viral infection at the time of the blood work
b
Participant was deemed weight restored by a study physician at the time, but elevated cholesterol was the primary reason for olanzapine discontinuation
c
Participant’s baseline level of amylase was elevated
ALT = Alanine aminotransferase. AST = Aspartate aminotransferase. HDL = High density lipoprotein cholesterol. LDL = Low density lipoprotein. TGW = Treatment goal weight.